Biodesix

About:

Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services.

Website: http://www.biodesix.com

Twitter/X: biodesixinc

Top Investors: Perceptive Advisors, CRG, Lincoln Park Capital Fund

Description:

Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring, and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops, and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’s first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’s CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.

Total Funding Amount:

$445M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Broomfield, Colorado, United States

Founded Date:

2005-01-01

Contact Email:

marketing(AT)biodesix.com

Founders:

David Brunel, Heinrich Röder, Robert E. Cawthorn

Number of Employees:

101-250

Last Funding Date:

2024-04-05

IPO Status:

Public

© 2025 bioDAO.ai